Glansectomy with or without a neoglans reconstruction is commonly performed for invasive penile cancer confined to the glans penis. The aim of penile-preserving procedures is to maintain sexual and ...

To evaluate oncologic and perioperative outcomes of extended pelvic lymph node dissection (PLND) during robot-assisted radical cystectomy (RARC) based on the location of lymph node positivity (LN+).

Intrinsic and acquired resistance to second-generation anti-androgens pose a significant clinical challenge in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Novel ...

Although prostate-specific antigen (PSA) testing is still widely used for prostate cancer screening, it is not cancer-specific and can lead to unnecessary invasive biopsies in patients without cancer.

This document defines the key considerations for developing and reporting an artificial intelligence (AI) interpretation model for the detection of clinically significant prostate cancer (PCa) at MRI ...

In 2025, prostate cancer is the most common cancer in Australia, regardless of gender, and is the second most common cause of cancer death despite the opportunities for cure. In 2016, Australian ...

In Michigan, around 50% of patients with localized renal masses of ≤7 cm (cT1RMs) are managed without immediate intervention, contradicting previous reports indicating active surveillance (AS) rates ...

Prostate cancer is the second most common cancer among men globally and the number of cases is expected to double from 2020 to 2040. A greater understanding of health system factors that can be ...

Mortgage lending bias is a critical driver of residential segregation, and may contribute to disparities in cancer survival. This study investigated the association between contemporary redlining and ...

Existing literature underscores racial and sociodemographic disparities in prostate cancer screening (PCS) in the USA. To evaluate whether traditional PCS disparities are evident within a health ...

• Ultra-low PSA Response (<0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes Interactive Poster Session: IP26-07; April 29, 9:30-11:30 a.m. PDT ...

Bladder cancer (BLCA) management presents complex clinical challenges requiring deep knowledge of current guidelines and clinical expertise. A recent study by Li et al. evaluated the performance of ...